

**DESCRIPTION**

|                           |  |
|---------------------------|--|
| <b>Species Reactivity</b> | Human  |
| <b>Specificity</b>        | Detects human Pro-BNP in direct ELISAs and Western blots. No cross-reactivity with recombinant human BNP (aa 103-134) is observed. |
| <b>Source</b>             | Monoclonal Rat IgG <sub>2A</sub> Clone # 370104  |
| <b>Purification</b>       | Protein A or G purified from hybridoma culture supernatant   |
| <b>Immunogen</b>          | <i>E. coli</i> -derived recombinant human Pro-BNP<br>His27-His134<br>Accession # P16860  |
| <b>Conjugate</b>          | Alexa Fluor 750<br>Excitation Wavelength: 749 nm<br>Emission Wavelength: 775 nm  |
| <b>Formulation</b>        | Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide   |

\*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

**Western Blot** Optimal dilution of this antibody should be experimentally determined.

**PREPARATION AND STORAGE**

**Shipping** The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

**BACKGROUND**

In cardiac tissue brain natriuretic peptide (BNP) is synthesized as 134 amino acid precursor (prepro-BNP), which is cleaved by proteases to form a 26 aa signal peptide and a 108 aa Pro-BNP (aa 27-134). Proteolytic digestion of Pro-BNP results in formation of 76 aa amino-terminal NT-proBNP (aa 27-102) and biologically active 32 aa BNP hormone molecule (aa 103-134). Both proBNP and NTpro-BNP circulate in human plasma and have been proposed as markers for early diagnosis of left ventricular dysfunction as well as prognostic markers of possible cardiac complications at patients with heart failure.

**PRODUCT SPECIFIC NOTICES**

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.